27 results on '"Carrera, Carlo Giovanni"'
Search Results
2. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
- Author
-
Gargiulo, Luigi, primary, Ibba, Luciano, additional, Malagoli, Piergiorgio, additional, Amoruso, Fabrizio, additional, Argenziano, Giuseppe, additional, Balato, Anna, additional, Bardazzi, Federico, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Damiani, Giovanni, additional, Dapavo, Paolo, additional, Dini, Valentina, additional, Franchi, Chiara, additional, Gaiani, Francesca Maria, additional, Girolomoni, Giampiero, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Loconsole, Francesco, additional, Marzano, Angelo Valerio, additional, Maurelli, Martina, additional, Megna, Matteo, additional, Orsini, Diego, additional, Sampogna, Francesca, additional, Travaglini, Massimo, additional, Valenti, Mario, additional, Costanzo, Antonio, additional, and Narcisi, Alessandra, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
- Author
-
Chiricozzi, Andrea, Costanzo, Antonio, Fargnoli, Maria Concetta, Malagoli, Piergiorgio, Piaserico, Stefano, Amerio, Paolo, Argenziano, Giuseppe, Balato, Nicola, Bardazzi, Federico, Bianchi, Luca, Carrera, Carlo Giovanni, Conti, Andrea, Dapavo, Paolo, De Simone, Clara, Loconsole, Francesco, Lo Schiavo, Ada, Malara, Giovanna, Musumeci, Maria Letizia, Parodi, Aurora, Peris, Ketty, Prignano, Francesca, Rongioletti, Franco, Talamonti, Marina, and Potenza, Concetta
- Published
- 2021
- Full Text
- View/download PDF
4. Commentary: Unmet Needs in Generalized Pustular Psoriasis in Clinical Practice
- Author
-
Balato, Anna, primary, Ambrogio, Francesca, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Chiricozzi, Andrea, additional, Esposito, Maria, additional, Piaserico, Stefano, additional, Teoli, Miriam, additional, and Gisondi, Paolo, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Palmoplantar pustulosis successfully treated with upadacitinib: Report of three cases
- Author
-
Gaiani, Francesca Maria, primary, Malagoli, Piergiorgio, additional, and Carrera, Carlo Giovanni, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
- Author
-
Chiricozzi, Andrea, primary, Megna, Matteo, additional, Giunta, Alessandro, additional, Carrera, Carlo Giovanni, additional, Dapavo, Paolo, additional, Balato, Anna, additional, Malagoli, Piergiorgio, additional, Mazzoccoli, Stella, additional, Parodi, Aurora, additional, Sabatino, Silvia, additional, Buzzoni, Carlotta, additional, Huang, Chu-Han, additional, and Narcisi, Alessandra, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
- Author
-
Gargiulo, Luigi, primary, Ibba, Luciano, additional, Malagoli, Piergiorgio, additional, Amoruso, Fabrizio, additional, Argenziano, Giuseppe, additional, Balato, Anna, additional, Bardazzi, Federico, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Damiani, Giovanni, additional, Dapavo, Paolo, additional, Dini, Valentina, additional, Fabbrocini, Gabriella, additional, Franchi, Chiara, additional, Gaiani, Francesca Maria, additional, Girolomoni, Giampiero, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Loconsole, Francesco, additional, Marzano, Angelo Valerio, additional, Megna, Matteo, additional, Sampogna, Francesca, additional, Travaglini, Massimo, additional, Costanzo, Antonio, additional, and Narcisi, Alessandra, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
- Author
-
Fargnoli, Maria Concetta, primary, Bardazzi, Federico, additional, Bianchi, Luca, additional, Dapavo, Paolo, additional, Fabbrocini, Gabriella, additional, Gisondi, Paolo, additional, Micali, Giuseppe, additional, Offidani, Anna Maria, additional, Pellacani, Giovanni, additional, Skroza, Nevena, additional, Angileri, Rosa Giuseppa, additional, Burlando, Martina, additional, Campanati, Anna, additional, Carrera, Carlo Giovanni, additional, Chiricozzi, Andrea, additional, Conti, Andrea, additional, Simone, Clara De, additional, Di Lernia, Vito, additional, Errichetti, Enzo, additional, Galluzzo, Marco, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Lembo, Serena, additional, Loconsole, Francesco, additional, Megna, Matteo, additional, Musumeci, Maria Letizia, additional, Prignano, Francesca, additional, Richetta, Antonio Giovanni, additional, Trovato, Emanuele, additional, Venturini, Marina, additional, Peris, Ketty, additional, and Pinton, Piergiacomo Calzavara, additional
- Published
- 2023
- Full Text
- View/download PDF
9. A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review.
- Author
-
Denaro, Nerina, Nazzaro, Gianluca, Murgia, Giulia, Scarfì, Federica, Cauchi, Carolina, Carrera, Carlo Giovanni, Cattaneo, Angelo, Solinas, Cinzia, Scartozzi, Mario, Marzano, Angelo Valerio, Garrone, Ornella, and Passoni, Emanuela
- Subjects
LITERATURE reviews ,PSORIASIS ,SYMPTOMS ,TUMORS ,DISEASE risk factors - Abstract
Psoriasis is a chronic immune-mediated disease that is linked to an increased risk of cancer. Although numerous studies have explored whether neoplasms are concurrent conditions or are induced by psoriasis, a definitive definition remains elusive. In this study, we conducted a comprehensive narrative literature review to offer practical guidance to oncologists and dermatologists regarding the initiation and discontinuation of biologics for psoriasis. The findings indicate that a customized approach is recommended for each patient, and that a history of malignancies does not constitute an absolute contraindication for biologics. Growing evidence supports the treatment of selected patients, emphasizing a nuanced assessment of benefits and risks. There is a lack of data specifying a safe timeframe to initiate biologics following a neoplasm diagnosis due to influences from cancer-related and patient-specific characteristics impacting prognosis. Some patients may continue anti-psoriasis therapy during cancer treatments. Enhanced comprehension of the biological mechanisms in cancer progression and the immune microenvironment of psoriasis holds promise for refining therapeutic strategies. In conclusion, a personalized treatment approach necessitates collaboration between oncologists and dermatologists, considering factors such as cancer prognosis, psoriasis clinical manifestations, patient characteristics, and preferences when making treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
- Author
-
Avallone, Gianluca, primary, Maronese, Carlo Alberto, additional, Murgia, Giulia, additional, Carrera, Carlo Giovanni, additional, Mastorino, Luca, additional, Roccuzzo, Gabriele, additional, Dapavo, Paolo, additional, Alberti-Violetti, Silvia, additional, Quaglino, Pietro, additional, Ribero, Simone, additional, and Marzano, Angelo Valerio, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Polymorphic rupioid psoriasis with chamomile‐like lesions: A case report
- Author
-
Aromolo, Italo Francesco, primary, Riva, Davide, additional, Cattaneo, Angelo, additional, Carrera, Carlo Giovanni, additional, Spigariolo, Cristina Beatrice, additional, and Marzano, Angelo Valerio, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
- Author
-
Stingeni, Luca, primary, Malara, Giovanna, additional, Conti, Andrea, additional, Di Costanzo, Luisa, additional, Carrera, Carlo Giovanni, additional, Burlando, Martina, additional, Malagoli, Piergiorgio, additional, Musumeci, Maria Letizia, additional, Bardazzi, Federico, additional, Brazzelli, Valeria, additional, Amerio, Paolo, additional, De Simone, Clara, additional, Trevisini, Sara, additional, Balato, Anna, additional, Megna, Matteo, additional, Loconsole, Francesco, additional, De Felice, Catia, additional, Bartezaghi, Marta, additional, Rausa, Alice, additional, Aloisi, Elisabetta, additional, Orsenigo, Roberto, additional, and Costanzo, Antonio, additional
- Published
- 2023
- Full Text
- View/download PDF
13. Mpox: an updated review of dermatological manifestations in the current outbreak.
- Author
-
Maronese, Carlo Alberto, Avallone, Gianluca, Aromolo, Italo Francesco, Spigariolo, Cristina Beatrice, Quattri, Eleonora, Ramoni, Stefano, Carrera, Carlo Giovanni, and Marzano, Angelo Valerio
- Subjects
MONKEYPOX ,SEXUALLY transmitted diseases ,ZOONOSES ,Q fever ,CUTANEOUS manifestations of general diseases - Abstract
Mpox is a disease caused by a double-stranded DNA orthopoxvirus discovered in 1958. In 2022, an outbreak on an unprecedented scale marked its transition from neglected, zoonotic disease circulating almost exclusively within African borders to sexually transmitted infection (STI) of international concern. Although phylogenetic evidence suggests progressive evolution from the strain associated with the 2018 outbreak in Nigeria, epidemiological links with previous cases have still not been completely elucidated. Clinically, mpox presents with systemic symptoms, such as fever, headache, malaise and a characteristic cutaneous eruption, similar to that of cognate viruses (e.g. smallpox). Mpox pseudopustules evolve through several stages, including umbilication and crusting, and resolve in the span of 2–3 weeks. The hallmarks that set the 2022 outbreak apart from classic mpox were a disproportionate number of cases occurring in men who have sex with men, an often localized cutaneous picture and a significant burden in terms of concomitant STIs. Investigations into the disease pathogenesis, related immune response, clinical and dermoscopic features, in addition to studies aimed at defining novel management strategies, have advanced mpox knowledge considerably. Herein, recent findings on mpox are reviewed, with a keen focus on dermatological manifestations and their implications in the current diagnostic scenario, reinforcing the pivotal role of dermatologists in managing suspect cases and preventing further spread of the contagion. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab
- Author
-
Aromolo, Italo Francesco, primary, Maronese, Carlo Alberto, additional, Moltrasio, Chiara, additional, Boggio, Francesca, additional, Violetti, Silvia Alberti, additional, Avallone, Gianluca, additional, Morini, Nicole, additional, Carrera, Carlo Giovanni, additional, Genovese, Giovanni, additional, and Marzano, Angelo Valerio, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Syphilis and monkeypox co-infection: Coincidence, synergy or asymptomatic carriage?
- Author
-
Ramoni, Stefano, primary, Maronese, Carlo Alberto, additional, Morini, Nicole, additional, Avallone, Gianluca, additional, Quattri, Eleonora, additional, Carrera, Carlo Giovanni, additional, Boggio, Francesca Laura, additional, and Marzano, Angelo Valerio, additional
- Published
- 2022
- Full Text
- View/download PDF
16. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study— IL PSO ( Italian landscape psoriasis )
- Author
-
Narcisi, Alessandra, primary, Valenti, Mario, additional, Gargiulo, Luigi, additional, Ibba, Luciano, additional, Amoruso, Fabrizio, additional, Argenziano, Giuseppe, additional, Bardazzi, Federico, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Damiani, Giovanni, additional, Dapavo, Paolo, additional, Dini, Valentina, additional, Franchi, Chiara, additional, Girolomoni, Giampiero, additional, Guarneri, Claudio, additional, Loconsole, Francesco, additional, Sampogna, Francesca, additional, Travaglini, Massimo, additional, Malagoli, Piergiorgio, additional, and Costanzo, Antonio, additional
- Published
- 2022
- Full Text
- View/download PDF
17. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach
- Author
-
De Simone, Clara, Dapavo, Paolo, Malagoli, Piergiorgio, Martella, Alessandro, Campanati, Anna, Campione, Elena, Errichetti, Enzo, Franchi, Chiara, Gambardella, Alessio, Megna, Matteo, Osti, Federica, Ribero, Simone, Zagni, Giovanni, Calzavara-Pinton, Piergiacomo, Fabbrocini, Gabriella, Amoruso, Giuseppe Fabrizio, Baglieri, Francesco, Biamonte, Anna Silvia, Bianchelli, Tommaso, Bigi, Laura, Bortoli, Jarno, Brunetti, Bruno, Buligan, Cinzia, Cagni, Elisabetta, Calderoni, Ombretta, Caputo, Alighiero, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Cicchelli, Stefano, De Natale, Flora, Di Maria, Domenico, Ferrari, Angelo Salvatore, Fogli, Emanuela, Forconi, Riccardo, Galeazzi, Augusto, Giovannini, Andrea, Giura, Maria Teresa, Iuculano, Massimo, Lazzaretti, Giuseppe, Leporati, Claudia, Magnanini, Massimiliano, Marconi, Barbara, Maruccia, Adriana, Miglietta, Roberta, Minuti, Anna, Mocci, Luigi, Modica, Sonia, Narcisi, Alessandra, Odorici, Giulia, Pazzaglia, Massimiliano, Peila, Rossana, Pertusi, Ginevra, Pezza, Michele, Pezzullo, Elio, Puccia, Nunzio, Raulo, Umberto, Rossi, Mariateresa, Rusignuolo, Sergio, Sapienza, Giada, Savarese, Catello, Scalisi, Mariaelena, Strippoli, Davide, Stroppiana, Elena, Tiberio, Rossana, Trischitta, Antonino, Tucci, Maria Giovanna, Vaira, Fabrizio, Verrone, Anna, Villa, Lucia, Zagni, Fabio, Zoccali, Andrea, De Simone, C, Dapavo, P, Malagoli, P, Martella, A, Campanati, A, Campione, E, Errichetti, E, Franchi, C, Gambardella, A, Megna, M, Osti, F, Ribero, S, Zagni, G, Calzavara-Pinton, P, Fabbrocini, G, Amoruso, G, Baglieri, F, Biamonte, A, Bianchelli, T, Bigi, L, Bortoli, J, Brunetti, B, Buligan, C, Cagni, E, Calderoni, O, Caputo, A, Carrera, C, Carugno, A, Chersi, K, Cicchelli, S, De Natale, F, Di Maria, D, Ferrari, A, Fogli, E, Forconi, R, Galeazzi, A, Giovannini, A, Giura, M, Iuculano, M, Lazzaretti, G, Leporati, C, Magnanini, M, Marconi, B, Maruccia, A, Miglietta, R, Minuti, A, Mocci, L, Modica, S, Narcisi, A, Odorici, G, Pazzaglia, M, Peila, R, Pertusi, G, Pezza, M, Pezzullo, E, Puccia, N, Raulo, U, Rossi, M, Rusignuolo, S, Sapienza, G, Savarese, C, Scalisi, M, Strippoli, D, Stroppiana, E, Tiberio, R, Trischitta, A, Tucci, M, Vaira, F, Verrone, A, Villa, L, Zagni, F, Zoccali, A, De Simone, Clara, Dapavo, Paolo, Malagoli, Piergiorgio, Martella, Alessandro, Campanati, Anna, Campione, Elena, Errichetti, Enzo, Franchi, Chiara, Gambardella, Alessio, Megna, Matteo, Osti, Federica, Ribero, Simone, Zagni, Giovanni, Calzavara-Pinton, Piergiacomo, Fabbrocini, Gabriella, Amoruso, Giuseppe Fabrizio, Baglieri, Francesco, Biamonte, Anna Silvia, Bianchelli, Tommaso, Bigi, Laura, Bortoli, Jarno, Brunetti, Bruno, Buligan, Cinzia, Cagni, Elisabetta, Calderoni, Ombretta, Caputo, Alighiero, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Cicchelli, Stefano, De Natale, Flora, Di Maria, Domenico, Ferrari, Angelo Salvatore, Fogli, Emanuela, Forconi, Riccardo, Galeazzi, Augusto, Giovannini, Andrea, Giura, Maria Teresa, Iuculano, Massimo, Lazzaretti, Giuseppe, Leporati, Claudia, Magnanini, Massimiliano, Marconi, Barbara, Maruccia, Adriana, Miglietta, Roberta, Minuti, Anna, Mocci, Luigi, Modica, Sonia, Narcisi, Alessandra, Odorici, Giulia, Pazzaglia, Massimiliano, Peila, Rossana, Pertusi, Ginevra, Pezza, Michele, Pezzullo, Elio, Puccia, Nunzio, Raulo, Umberto, Rossi, Mariateresa, Rusignuolo, Sergio, Sapienza, Giada, Savarese, Catello, Scalisi, Mariaelena, Strippoli, Davide, Stroppiana, Elena, Tiberio, Rossana, Trischitta, Antonino, Tucci, Maria Giovanna, Vaira, Fabrizio, Verrone, Anna, Villa, Lucia, Zagni, Fabio, and Zoccali, Andrea
- Subjects
Aerosols ,long-term ,proactive management ,Dermatology ,psoriasis ,Betamethasone ,Drug Combinations ,Treatment Outcome ,Recurrence ,consensus ,Cal/BD ,adherence ,consensu ,Humans ,Dermatologic Agents ,psoriasi - Abstract
Background: Although long-term management of psoriasis is paramount, this approach is challenging in clinical practice. In the recent PSO-LONG trial, a fixed-dose combination of betamethasone dipropionate (BD) and calcipotriol (Cal) foam applied twice a week on non-consecutive days for 52 weeks (proactive treatment) reduced the risk of relapse. However, the role of Cal/BD foam in the long-term management of psoriasis needs further clarifications. The ProActive Management (PAM) program, a nationwide Italian project, aims at reaching a consensus on the role of proactive management of psoriasis. Methods: A steering committee generated some statements through the nominal group technique (NGT). The statements were voted by an expert panel in an adapted Delphi voting process. Results: Eighteen statements were proposed, and the majority of them (14/18) reached a consensus during the Delphi voting. The need to provide long-term proactive topical treatment to reduce the risk of relapse for the treatment of challenging diseases sites or in patients where phototherapy or systemic therapies are contraindicated/ineffective was widely recognized. A consensus was reached about the possibility to associate the proactive treatment with systemic and biological therapies, without the need for dose intensification, thus favoring a prolonged remission. Moreover, the proactive treatment was recognized as more effective than weekend therapy in increasing time free from relapses. Approaches to improve adherence, on the other hand, need further investigation. Conclusions: The inclusion in guidelines of a proactive strategy among the effective treatment options will be a fundamental step in the evolution of a mild-moderate psoriasis therapeutic approach.
- Published
- 2022
18. Reply to “Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the “minimal disease activity” parameter”
- Author
-
Murgia, Giulia, primary, Maronese, Carlo Alberto, additional, Carrera, Carlo Giovanni, additional, Cattaneo, Angelo, additional, and Marzano, Angelo Valerio, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis).
- Author
-
Narcisi, Alessandra, Valenti, Mario, Gargiulo, Luigi, Ibba, Luciano, Amoruso, Fabrizio, Argenziano, Giuseppe, Bardazzi, Federico, Burlando, Martina, Carrera, Carlo Giovanni, Damiani, Giovanni, Dapavo, Paolo, Dini, Valentina, Franchi, Chiara, Girolomoni, Giampiero, Guarneri, Claudio, Loconsole, Francesco, Sampogna, Francesca, Travaglini, Massimo, Malagoli, Piergiorgio, and Costanzo, Antonio
- Subjects
CLINICAL trials ,PSORIASIS ,ELECTRONIC health records ,BODY mass index ,RETROSPECTIVE studies - Abstract
Background: Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin‐23. It is approved for treatment of moderate–severe chronic plaque psoriasis. Objectives: We conducted a 52‐week retrospective study to assess the effectiveness and safety of tildrakizumab in a real‐life setting. Methods: Our retrospective study included 237 consecutive adults with moderate‐to‐severe plaque psoriasis, enrolled in 10 different Italian centres, treated with tildrakizumab up to Week 52. Patient characteristics, comorbidities, previous treatments and the PASI (Psoriasis Area and Severity Index) score at each visit (baseline, Week 16, Week 28 and Week 52) were retrieved from the electronic medical records. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI with respect to baseline PASI were registered. Results: At Week 52, 90.91%, 73.55% and 58.68% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. An absolute PASI ≤ 2 was reached by 85.95% at Week 52. Compared with Phase 3 clinical trials, we observed similar rates of PASI 75/90 responses and higher percentages of patients achieving PASI 100. Patients who had not responded to previous biologic treatments and patients with cardio‐metabolic comorbidities were significantly more likely to achieve PASI 100 at Week 28 and PASI 90 at Week 52. The higher body mass index did not interfere with the odds of reaching PASI 75/90/100 at each time point. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment because of adverse events. Conclusion: Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in 'real‐life' clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab.
- Author
-
Aromolo, Italo Francesco, Maronese, Carlo Alberto, Moltrasio, Chiara, Boggio, Francesca, Violetti, Silvia Alberti, Avallone, Gianluca, Morini, Nicole, Carrera, Carlo Giovanni, Genovese, Giovanni, and Marzano, Angelo Valerio
- Subjects
PYODERMA gangrenosum ,MONONUCLEAR leukocytes ,JUVENILE idiopathic arthritis - Abstract
CPD questions Learning objective To gain up-to-date knowledge about the pathogenesis of pyoderma gangrenosum and the relationship between treatment with brodalumab and pyoderma gangrenosum. Pyoderma gangrenosum (PG) is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
21. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis
- Author
-
Carrera, Carlo Giovanni, primary, Dapavo, Paolo, additional, Malagoli, Piergiorgio, additional, Naldi, Luigi, additional, Arancio, Luisa, additional, Gaiani, Francesca, additional, Egan, Colin Gerard, additional, Di Mercurio, Marco, additional, and Cattaneo, Angelo, additional
- Published
- 2017
- Full Text
- View/download PDF
22. Cheilitis granulomatosa associated with lupus erythematosus discoid and treated with methotrexate: report of a case
- Author
-
Nazzaro, Gianluca, Muratori, Simona, Carrera, Carlo Giovanni, Coggi, Antonella, and Gianotti, Raffaele
- Subjects
Lupus erythematosus, discoid ,Methotrexate ,Melkersson-Rosenthal Syndrome ,skin and connective tissue diseases - Abstract
We present the rare case of a 47-year-old patient, suffering from cheilitis granulomatosa and lupus erythematosus discoid: this association is really exceptional because only once reported in English literature. In addition, the treatment of cheilitis granulomatosa is a challenge for the dermatologist: the gold standard, represented by steroids, is in fact designed as a short-time option. Our report confi rms the good efficacy of methotrexate as a steroid-sparing agent.
- Published
- 2015
23. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
- Author
-
Carrera, Carlo Giovanni, Dapavo, Paolo, Malagoli, Piergiorgio, Naldi, Luigi, Arancio, Luisa, Gaiani, Francesca, Egan, Colin Gerard, Di Mercurio, Marco, and Cattaneo, Angelo
- Subjects
- *
PSORIATIC arthritis , *PSORIASIS , *LOGISTIC regression analysis , *ADALIMUMAB , *ETANERCEPT - Abstract
Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response. Results: Two hundred and fifty five patients were included. No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4%), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4%, p =.02). More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23%, p <.001) or ustekinumab (65.7 vs. 44.6%, p =.003). Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept. PASI100 response was achieved in ∼43% of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3%), increasing to 92.5, 85.4 and 35.7%, respectively by six months. PASI100 response was associated with psoriasis nail involvement or genital psoriasis. Conclusion: In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Cheilitis granulomatosa associated with lupus erythematosus discoid and treated with methotrexate: report of a case
- Author
-
Nazzaro, Gianluca, primary, Muratori, Simona, additional, Carrera, Carlo Giovanni, additional, Coggi, Antonella, additional, and Gianotti, Raffaele, additional
- Published
- 2015
- Full Text
- View/download PDF
25. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
- Author
-
Luca Stingeni, Giovanna Malara, Andrea Conti, Luisa Di Costanzo, Carlo Giovanni Carrera, Martina Burlando, Piergiorgio Malagoli, Maria Letizia Musumeci, Federico Bardazzi, Valeria Brazzelli, Paolo Amerio, Clara De Simone, Sara Trevisini, Anna Balato, Matteo Megna, Francesco Loconsole, Catia De Felice, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo, Stingeni, Luca, Malara, Giovanna, Conti, Andrea, Di Costanzo, Luisa, Carrera, Carlo Giovanni, Burlando, Martina, Malagoli, Piergiorgio, Musumeci, Maria Letizia, Bardazzi, Federico, Brazzelli, Valeria, Amerio, Paolo, De Simone, Clara, Trevisini, Sara, Balato, Anna, Megna, Matteo, Loconsole, Francesco, De Felice, Catia, Bartezaghi, Marta, Rausa, Alice, Aloisi, Elisabetta, Orsenigo, Roberto, and Costanzo, Antonio
- Subjects
Hospital Anxiety and Depression Scale ,Clinical, Cosmetic and Investigational Dermatology ,patient-reported outcomes ,Dermatology Quality of Life Index ,PASI ,Dermatology ,patient-reported outcome ,plaque psoriasis - Abstract
Luca Stingeni,1 Giovanna Malara,2,3 Andrea Conti,4 Luisa Di Costanzo,5 Carlo Giovanni Carrera,6 Martina Burlando,7 Piergiorgio Malagoli,8 Maria Letizia Musumeci,9 Federico Bardazzi,10 Valeria Brazzelli,11 Paolo Amerio,12 Clara De Simone,13,14 Sara Trevisini,15 Anna Balato,16 Matteo Megna,17 Francesco Loconsole,18 Catia De Felice,19 Marta Bartezaghi,20 Alice Rausa,20 Elisabetta Aloisi,20 Roberto Orsenigo,20 Antonio Costanzo21,22 On behalf of the SUPREME Study Group1Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy; 2Dermatology Unit, Hospital âBianchi Melacrino Morelliâ, Reggio Calabria, Italy; 3Department of Dermatology, Papardo Hospital, Messina, Italy; 4Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini, Italy; 5Department of Dermatology, âGaetano Rummoâ Hospital, Benevento UOC Dermatologia, AO G. Rummo, Benevento, Italy; 6U.O. Dermatologia, Fondazione IRCCS Caâ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 7IRCCS San Martino Polyclinic Hospital, Di.S.Sal. Section of Dermatology, Genoa, Italy; 8Dermatology Unit IRCCS Policlinico San Donato, Milan, Italy; 9Dermatology Clinic, University of Catania, Catania, Italy; 10Division of Dermatology, University Hospital Policlinico âS. Orsola-Malpighiâ, Bologna, Italy; 11Institute of Dermatology, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 12Dermatologic Clinic, G. DâAnnunzio University, Chieti, Italy; 13Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 14Fondazione Policlinico Universitario A. Gemelli â IRCCS, Rome, Italy; 15Dermatology Department, University of Trieste, Trieste, Italy; 16Dermatology Unit, University of Campania âLuigi Vanvitelliâ, Naples, Italy; 17Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 18Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; 19Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy; 20Novartis Farma SpA, Origgio, Italy; 21Unit of Dermatology, IRCCS Humanitas Research Hospital, Milan, Italy; 22Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence: Luca Stingeni, Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy, Tel +39075-5783881, Email luca.stingeni@unipg.itPurpose: Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24.Patients and Methods: The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test.Results: Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; P< 0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; P=0.0779) and 24 (83.2% vs 79.7%; P=0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (â 10.9 vs â 8.1, respectively, in females vs males; P=0.0004).Conclusion: In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.Keywords: plaque psoriasis, PASI, patient-reported outcomes, Dermatology Quality of Life Index, Hospital Anxiety and Depression Scale
- Published
- 2023
26. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
- Author
-
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, Paolo Dapavo, Gabriella Fabbrocini, Paolo Gisondi, Giuseppe Micali, Anna Maria Offidani, Giovanni Pellacani, Nevena Skroza, Rosa Giuseppa Angileri, Martina Burlando, Anna Campanati, Carlo Giovanni Carrera, Andrea Chiricozzi, Andrea Conti, Clara De Simone, Vito Di Lernia, Enzo Errichetti, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Matteo Megna, Maria Letizia Musumeci, Francesca Prignano, Antonio Giovanni Richetta, Emanuele Trovato, Marina Venturini, Ketty Peris, Piergiacomo Calzavara Pinton, Fargnoli, Maria Concetta, Bardazzi, Federico, Bianchi, Luca, Dapavo, Paolo, Fabbrocini, Gabriella, Gisondi, Paolo, Micali, Giuseppe, Offidani, Anna Maria, Pellacani, Giovanni, Skroza, Nevena, Angileri, Rosa Giuseppa, Burlando, Martina, Campanati, Anna, Carrera, Carlo Giovanni, Chiricozzi, Andrea, Conti, Andrea, Simone, Clara De, Di Lernia, Vito, Errichetti, Enzo, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Lembo, Serena, Loconsole, Francesco, Megna, Matteo, Musumeci, Maria Letizia, Prignano, Francesca, Richetta, Antonio Giovanni, Trovato, Emanuele, Venturini, Marina, Peris, Ketty, and Pinton, Piergiacomo Calzavara
- Subjects
brodalumab ,Delphi ,consensus ,statement ,psoriasis ,consensu ,brodalumab therapy psoriasis ,General Medicine - Abstract
Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = “strongly disagree” to 5 = “strongly agree”) using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form “main principles” and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.
- Published
- 2023
27. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
- Author
-
De Simone C, Dapavo P, Malagoli P, Martella A, Campanati A, Campione E, Errichetti E, Franchi C, Gambardella A, Megna M, Osti F, Ribero S, Zagni G, Calzavara-Pinton P, Fabbrocini G, Amoruso GF, Baglieri F, Biamonte AS, Bianchelli T, Bigi L, Bortoli J, Brunetti B, Buligan C, Cagni E, Calderoni O, Calzavara-Pinton P, Campanati A, Caputo A, Carrera CG, Carugno A, Chersi K, Cicchelli S, De Natale F, De Simone C, Dapavo P, Di Maria D, Errichetti E, Fabbrocini G, Ferrari AS, Fogli E, Forconi R, Franchi C, Galeazzi A, Gambardella A, Giovannini A, Giura MT, Iuculano M, Lazzaretti G, Leporati C, Magnanini M, Malagoli P, Marconi B, Martella A, Maruccia A, Megna M, Miglietta R, Minuti A, Mocci L, Modica S, Narcisi A, Odorici G, Osti F, Pazzaglia M, Peila R, Pertusi G, Pezza M, Pezzullo E, Puccia N, Raulo U, Ribero S, Rossi M, Rusignuolo S, Sapienza G, Savarese C, Scalisi M, Strippoli D, Stroppiana E, Tiberio R, Trischitta A, Tucci MG, Vaira F, Verrone A, Villa L, Zagni F, and Zoccali A
- Subjects
- Humans, Consensus, Betamethasone, Aerosols, Treatment Outcome, Recurrence, Drug Combinations, Dermatologic Agents therapeutic use, Psoriasis drug therapy
- Abstract
Background: Although long-term management of psoriasis is paramount, this approach is challenging in clinical practice. In the recent PSO-LONG trial, a fixed-dose combination of betamethasone dipropionate (BD) and calcipotriol (Cal) foam applied twice a week on non-consecutive days for 52 weeks (proactive treatment) reduced the risk of relapse. However, the role of Cal/BD foam in the long-term management of psoriasis needs further clarifications. The ProActive Management (PAM) program, a nationwide Italian project, aims at reaching a consensus on the role of proactive management of psoriasis., Methods: A steering committee generated some statements through the nominal group technique (NGT). The statements were voted by an expert panel in an adapted Delphi voting process., Results: Eighteen statements were proposed, and the majority of them (14/18) reached a consensus during the Delphi voting. The need to provide long-term proactive topical treatment to reduce the risk of relapse for the treatment of challenging diseases sites or in patients where phototherapy or systemic therapies are contraindicated/ineffective was widely recognized. A consensus was reached about the possibility to associate the proactive treatment with systemic and biological therapies, without the need for dose intensification, thus favoring a prolonged remission. Moreover, the proactive treatment was recognized as more effective than weekend therapy in increasing time free from relapses. Approaches to improve adherence, on the other hand, need further investigation., Conclusions: The inclusion in guidelines of a proactive strategy among the effective treatment options will be a fundamental step in the evolution of a mild-moderate psoriasis therapeutic approach., (© 2022 The Authors. International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.